Biogen completes Reata acquisition; SKYCLARYS launch underway in U.S.

BIOGEN INC.

Acquired SKYCLARYS (omaveloxolone), first FDA-approved treatment for Friedreich's ataxia.
Over 1,000 patient start forms submitted in the U.S. since launch; EU review ongoing.
Deal expected slightly dilutive to Non-GAAP EPS in 2023, neutral in 2024, accretive from 2025.
Biogen to update 2023 financial guidance with Q3 earnings release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.